Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2010
12/29/2010WO2010149968A1 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
12/29/2010WO2010149944A1 Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
12/29/2010WO2010149943A1 New compounds and medical use
12/29/2010WO2010149817A1 Dioxanes derived from regrouping carbohydrates and c-glycosides, method for obtaining same, and uses thereof
12/29/2010WO2010149786A1 Pyrido [2, 3-d] pyrimidines as wnt antagonists for treatment of cancer and arthritis
12/29/2010WO2010149783A1 Tricyclic pyrimidine derivatives as wnt antagonists
12/29/2010WO2010149771A1 Novel compound useful for the treatment of degenerative and inflammatory diseases
12/29/2010WO2010149758A1 Antifungal 1, 2, 4-triazolyl derivatives
12/29/2010WO2010149755A1 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
12/29/2010WO2010149666A1 Methods for treating neoplasia
12/29/2010WO2010149459A1 Use of hat inhibitors and tmprss2 inhibitors as medicaments
12/29/2010WO2010149414A1 5-mercapto-[1, 2, 4] triazolylmethyl-cyclopentanol compounds and their agricultural and pharmaceutical uses
12/29/2010WO2010149394A1 Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors
12/29/2010WO2010149337A1 Process for preparation of 1,2-diamino-cyclohexane-platinum (ii) complexes
12/29/2010WO2010149326A1 Acid-labile trigger units
12/29/2010WO2010149257A1 Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators
12/29/2010WO2010148577A1 Antitumor and immunity-regulating pharmaceutical composition of traditional chinese medicine, preparation method and use for same
12/29/2010WO2010148501A1 Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
12/29/2010WO2010148496A1 Lipidated tumor- associated antigens and immunotherapeutic compositions
12/29/2010WO2010125471A3 Gene vector
12/29/2010WO2010101353A9 Composition containing human serum albumin-timp-2 fusion protein and anti-cancer drug for preventing or treating cancer
12/29/2010WO2010088564A3 Compositions and methods for the treatment of cancer
12/29/2010WO2010079406A9 Compounds and uses thereof for treating inflammation and modulating immune responses
12/29/2010EP2267454A2 Diagnosis and prevention of cancer cell invasion
12/29/2010EP2267431A2 Gas sensor
12/29/2010EP2267125A1 Cancer cell motility and cancer cell infiltration inhibitor
12/29/2010EP2267118A1 Method for production of transfected cell
12/29/2010EP2267117A2 Differentiation modulating agents and uses therefor
12/29/2010EP2267032A2 Method of administering therapeutic polypeptides, and polypeptides therefor
12/29/2010EP2267027A2 Method of administering therapeutic polypeptides, and polypeptides therefor
12/29/2010EP2267026A1 Albumin fusion proteins
12/29/2010EP2267023A2 KDR peptides and vaccines comprising the same
12/29/2010EP2267022A2 KDR peptides and vaccines comprising the same
12/29/2010EP2267021A2 KDR peptides and vaccines comprising the same
12/29/2010EP2267014A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266987A1 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
12/29/2010EP2266986A1 Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor
12/29/2010EP2266985A1 Tricyclic Pyrimidine Derivatives as Wnt antagonists
12/29/2010EP2266984A1 Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
12/29/2010EP2266978A1 Novel physiologically active substances
12/29/2010EP2266968A2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
12/29/2010EP2266964A1 Acid-labile trigger units
12/29/2010EP2266954A1 Novel bifunctional chelating compounds containing hydroxamic acid residues
12/29/2010EP2266953A1 Novel bifunctional chelating compounds containing hydroxamic acid residues
12/29/2010EP2266628A2 Method of determining the susceptibility to bone meatastases by EPhA2 expression
12/29/2010EP2266624A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
12/29/2010EP2266618A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266617A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266614A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266611A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266610A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266609A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266608A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
12/29/2010EP2266607A2 Immunoconjugates for treating cancer
12/29/2010EP2266604A2 Adjuvant systems and vaccines
12/29/2010EP2266603A1 Tumour vaccines
12/29/2010EP2266583A1 Gene expression inhibitor selective for matrix metalloproteinase-9 gene
12/29/2010EP2266577A1 Multi-substitued selective androgen receptor modulators and methods of use therof
12/29/2010EP2266573A1 Fulvestrant formulation
12/29/2010EP2266572A1 Use of pyrimidylaminobenzamide derivatives for the treatment of hypereosinophilic syndrome
12/29/2010EP2266570A1 Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders
12/29/2010EP2266562A1 Use of derivatives of indoles for the treatment of cancer
12/29/2010EP2266560A1 Benzothiophenes, formulations containing same, and methods
12/29/2010EP2266552A2 Methods of inducing terminal differentiation
12/29/2010EP2266537A2 Compositions and methods for treating cancer
12/29/2010EP2265626A2 Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
12/29/2010EP2265623A1 Mitochondrially delivered anti-cancer compounds
12/29/2010EP2265620A1 Spiro derivatives of parthenin as novel anticancer agents
12/29/2010EP2265618A2 Aurora kinase inhibitors
12/29/2010EP2265616A1 Furo-and thieno[3,2-c]pyridines
12/29/2010EP2265615A1 Imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
12/29/2010EP2265614A1 Imidazo [1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
12/29/2010EP2265613A1 Quinazoline linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
12/29/2010EP2265610A1 Pyrazole [3, 4-b]pyridine raf inhibitors
12/29/2010EP2265609A1 Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
12/29/2010EP2265607A1 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
12/29/2010EP2265599A2 Crystal form of phenylamino pyrimidine derivative
12/29/2010EP2265598A2 Novel hsp90 inhibitory carbazole derivatives, compositions containing same, and use thereof
12/29/2010EP2265591A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
12/29/2010EP2265584A1 Hydroxyalkanyl amides as modulators of chemokine receptor activity
12/29/2010EP2265580A1 Novel method for the production of sulphonylpyrroles as hdac inhibitors
12/29/2010EP2265574A1 N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
12/29/2010EP2265275A2 Antiviral therapeutic agents
12/29/2010EP2265274A2 Methotrexate adjuvants to reduce toxicity and methods for using the same
12/29/2010EP2265270A1 2-aminopyridine kinase inhibitors
12/29/2010EP2265174A1 Functionalized magnetic nanoparticles and methods of use thereof
12/29/2010EP2265126A1 Methods and compositions for controlled delivery of phytochemical agents
12/29/2010EP2049546B1 Dihydrofuro pyrimidines as akt protein kinase inhibitors
12/29/2010EP1856153B1 Ykl-40 monoclonal antibodies
12/29/2010EP1828249B1 Biomarkers for pre-selection of patients for anti-igf1r therapy
12/29/2010EP1810681B1 Intestinal polyp inhibitor
12/29/2010EP1660134B1 Conjugates of hydroxyalkyl starch and g-csf
12/29/2010EP1599503B1 Endothelial cell specific antibodies and uses thereof
12/29/2010EP1576959B1 Softgel of nlkj (neutral lipids obtained from kernels of job's tears) for treating prostate diseases
12/29/2010EP1530568B1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE
12/29/2010EP1529062B1 Therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction
12/29/2010EP1494705B1 A composition and method for killing of tumours
12/29/2010EP1438052B1 Quinazolin-4-ones as inhibitors of human phosphatidylinositol 3-kinase delta
12/29/2010EP1315519B1 Pharmaceutical compositions and methods useful for treating cancer or liver fibrosis
12/29/2010EP1001946B1 QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
1 ... 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 ... 2211